WhatControl software that dynamically optimizes power split between different motor types (EESM + PMSM) in dual-motor EVs, maximizing efficiency across all driving conditions rather than defaulting to one motor.
SignalCommenters noted frustration that dual-motor setups (one permanent magnet, one induction/EESM) often fail to use the secondary motor even when it would be more efficient, because the drag losses from the permanent magnet motor make switching counterproductive — the control problem is unsolved.
Why NowMulti-motor EV architectures are becoming standard in premium vehicles, and the efficiency gap between motor types at different operating points (city vs highway) is well-documented but poorly exploited by current control systems.
MarketEV OEMs with dual-motor platforms (most premium EVs); embedded software licensing at $5-20 per unit across millions of vehicles; competes with in-house OEM controls teams who are struggling with this exact problem.
MoatProprietary control algorithms validated across real drive cycles, plus integration partnerships with specific OEM platforms creating switching costs.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.